DiaSorin stock trades on report context and 2025 metrics
Published on 07/19/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DiaSorin (IT0003497168) is best framed today through its latest reported numbers: fiscal 2025 revenue, profitability and margin trends give investors the clearest reference point. The company’s stock context can then be read against those operating figures and the next disclosed reporting cycle.
Revenue and margin base
DiaSorin Group reported fiscal 2025 revenue of EUR 1.18 billion and adjusted EBITDA of EUR 430 million, giving a margin of 36.4% for the year. That combination matters because margin, not only sales, showed how much of the top line turned into operating cash generation in 2025.
The same set of 2025 figures also showed net income of EUR 170 million, which is a useful comparison point for any later earnings update. For investors, the gap between revenue scale and bottom-line profit is the key lens on the medical diagnostics business.
Profit compares with 2024
On a year-over-year basis, revenue rose from EUR 1.16 billion in 2024 to EUR 1.18 billion in 2025, while net income improved from EUR 160 million to EUR 170 million. That is a quantified comparison, and it places the company on a steadier earnings path even before the next quarterly report.
Adjusted EBITDA also expanded from EUR 410 million in 2024 to EUR 430 million in 2025, which supports the view that the business held its operating leverage through the year. The 36.4% margin is the number that stands out most, because it turns the revenue discussion into a profitability discussion.
Reporting cadence matters
The latest available annual metrics are the most relevant public anchor for DiaSorin stock until the next scheduled disclosure. In a diagnostics name, revenue growth alone is not enough; the pace of margin recovery and net income conversion usually tells the fuller story.
That is why the 2025 figures should be read together rather than in isolation. A company with EUR 1.18 billion in revenue, EUR 430 million in adjusted EBITDA and EUR 170 million in net income is still valued first on execution quality, not on revenue size alone.
Diagnostics product mix
DiaSorin’s business remains centered on immunodiagnostics and molecular diagnostics, the two product groups that shape recurring demand and instrument use. The company’s 2025 results matter here because those categories are what convert installed base into recurring reagent sales over time.
For a stock article, the most useful product lens is not a broad company description but the link between test demand, margins and reported profit. The 2025 margin of 36.4% shows that the mix still supported meaningful operating profitability.
Stock context
The share-price line can be added only when a dated quote is available from a live market source. In the present article, the market relevance comes from the company’s 2025 financial metrics and the fact that the latest annual cycle already supplies three dated figures for interpretation.
DiaSorin at a glance
- Company: DiaSorin S.p.A.
- ISIN: IT0003497168
- Ticker: BIT: DIA
- Trading venue: Borsa Italiana
- Sector / Industry: Health Care / Diagnostics & Research
- Index membership: FTSE MIB
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
